

Resource Summary Report

Generated by [NIF](#) on Sep 2, 2026

SiHa

RRID:CVCL_0032

Type: Cell Line

Proper Citation

CLS Cat# 305023, RRID:CVCL_0032

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0032

Proper Citation: CLS Cat# 305023, RRID:CVCL_0032

Description: Cell line SiHa is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related cervical squamous cell carcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1394225](#), [PMID:2990217](#), [PMID:3029430](#), [PMID:3029760](#), [PMID:3518877](#), [PMID:5529598](#), [PMID:10423141](#), [PMID:15531914](#), [PMID:16957166](#), [PMID:17311676](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20429727](#), [PMID:21439369](#), [PMID:22412903](#), [PMID:23881600](#), [PMID:24134916](#), [PMID:24201445](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28261610](#), [PMID:29156801](#), [PMID:30760827](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35198691](#), [PMID:35421932](#), [PMID:35692560](#), [PMID:35839778](#)

Comments: Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (PubMed=24201445)., Population: Japanese., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SiHa

Synonyms: Siha, SIHA

Cross References: BTO:BTO_0002210, CLO:CLO_0009017, EFO:EFO_0002379, MCCL:MCC:0000451, CLDB:cl4298, CLDB:cl4299, CLDB:cl4900,

AddexBio:C0008002/372, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:HTB-35, BioGRID_ORCS_Cell_line:1796, BioSample:SAMN03473215, BioSample:SAMN10989623, cancercellines:CVCL_0032, CCRID:1101HUM-PUMC000294, CCRID:1102HUM-NIFDC00092, CCRID:3101HUMSCSP5058, CCRID:3101HUMTCHu113, CCRID:4201HUM-CCTCC00110, CCTCC:GDC0110, Cell_Model_Passport:SIDM01093, ChEMBL-Cells:ChEMBL3307968, ChEMBL-Targets:ChEMBL612542, CLS:305023, Cosmic:760220, Cosmic:809229, Cosmic:846184, Cosmic:877467, Cosmic:925356, Cosmic:928911, Cosmic:930297, Cosmic:1019306, Cosmic:1131517, Cosmic:1193028, Cosmic:1201773, Cosmic:1324212, Cosmic:1995627, Cosmic:2301542, Cosmic:2660193, Cosmic:2791018, Cosmic:2816217, Cosmic-CLP:930297, DepMap:ACH-000556, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:930297, GEO:GSM113866, GEO:GSM226740, GEO:GSM226876, GEO:GSM253302, GEO:GSM675738, GEO:GSM685444, GEO:GSM722576, GEO:GSM722577, GEO:GSM723057, GEO:GSM723058, GEO:GSM1670422, GEO:GSM1716411, GEO:GSM1716412, GEO:GSM1716413, GEO:GSM1716414, GEO:GSM1716415, GEO:GSM1716416, GEO:GSM1716423, GEO:GSM1716424, GEO:GSM1716425, GEO:GSM1716426, GEO:GSM7701382, IARC_TP53:21696, ICLC:HTL98017, IGRhCellID:SiHa, IZSLER:BS TCL 112, KCB:KCB 2013026YJ, KCLB:30035, LINCS_LDP:LCL-1542, Pharmacodb:SiHa_1377_2019, PRIDE:PXD001806, PRIDE:PXD005466, PRIDE:PXD029773, PRIDE:PXD030304, PRIDE:PXD030885, Progenetix:CVCL_0032, PubChem_Cell_line:CVCL_0032, TOKU-E:3119, Wikidata:Q54953470

ID: CVCL_0032

Vendor: CLS

Catalog Number: 305023

Record Creation Time: 20220923T071552+0000

Record Last Update: 20260830T000610+0000

Ratings and Alerts

No rating or validation information has been found for SiHa.

No alerts have been found for SiHa.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1434 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu J, et al. (2026) M5C-driven stabilization of SERPINB5 promotes cervical cancer progression and chemotherapy resistance. *Cell death & disease*, 17(1), 215.

Malfatti MC, et al. (2026) The cooperative regulation of miR-221 by APE1 and AUF1 impacts p27Kip1 defining a miR signature relevant for cervical cancer. *FEBS open bio*, 16(6), 1222.

Cintra RC, et al. (2026) Targeted modulation of IGFL2-AS1 reveals its translational potential in cervical adenocarcinoma. *Molecular oncology*, 20(6), 1643.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Gies S, et al. (2026) Th17 cells favor migration and invasiveness of cervical cancer cells under hypoxia in an IGF2BP2-dependent manner. *International journal of cancer*, 158(11), 3021.

Su Q, et al. (2026) Galectin-1-Targeted Type-I/II Photosensitizers Activate the NF- κ B Pathway to Enhance Immunity and Treat High-Risk HPV-Associated Cervical Lesions. *ACS applied materials & interfaces*, 18(2), 3599.

Lou H, et al. (2026) PIK3CA mutant cervical cancer is selectively suppressed by PI3K γ inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy. *Neoplasia (New York, N.Y.)*, 76, 101305.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).

Talpe-Nunes V, et al. (2026) GATA3 Inhibits the Expression of Viral E6/E7 Genes, and Its Expression Is Compromised During HPV-Mediated Cervical Carcinogenesis. *Journal of medical virology*, 98(7), e71034.

Li L, et al. (2026) Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage. *Cancer cell*.

Li C, et al. (2026) A tumor-resident bacterium promotes cervical cancer progression through lysoPC-mediated c-Jun/c-Fos activation. *Cell reports*, 45(3), 117079.

Tang W, et al. (2026) Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells. *Journal of translational medicine*, 24(1).

Chhokar A, et al. (2026) Development of a novel multi-locus Flow-FISH based assay for detection of progressive cervical precancer lesions. *BMC cancer*, 26(1).

Punziano C, et al. (2026) Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. *Molecular oncology*.

Pan Y, et al. (2026) p38 inhibition restores chemosensitivity of tumor cells by disrupting oligomerized breast cancer resistance protein membrane trafficking. *iScience*, 29(1),

114359.

Li J, et al. (2026) Alkyltriphenylphosphonium Binding to Cardiolipin Triggers Oncosis in Cancer Cells. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e10237.

Chen D, et al. (2026) Manganese Biomineralized Ferritin Nanoplatfoms with Shielding and Stimuli-Responsive Release for Potentiated Ferroptosis and Multimodal Ovarian Cancer Therapy. *International journal of nanomedicine*, 21, 548411.

Zhang Y, et al. (2026) Dual-specificity phosphatase 14 inhibits the growth of cervical cancer cells by regulating the transforming growth factor-beta-activated kinase 1 and NOD-like receptor pyrin domain containing 3 inflammatory pathways. *The Journal of international medical research*, 54(4), 3000605261441200.

Abadia ACM, et al. (2026) Comparative Evaluation of the Cytotoxic Effect of *Dysphania ambrosioides* Extracts Against Human Breast and Cervical Cancer Cells. *Chemistry & biodiversity*, 23(7), e71452.

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.